Astrana Health (NASDAQ:ASTH) Issues Quarterly Earnings Results

Astrana Health (NASDAQ:ASTH) posted its quarterly earnings data on Thursday. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.45, FiscalAI reports. The business had revenue of $965.10 million for the quarter, compared to the consensus estimate of $949.21 million. Astrana Health had a net margin of 0.71% and a return on equity of 5.59%. The company’s revenue was up 55.6% compared to the same quarter last year. During the same period last year, the firm posted $0.42 earnings per share.

Here are the key takeaways from Astrana Health’s conference call:

• Astrana reported a strong Q1 — $965.1M revenue (+56% YoY), adjusted EBITDA of $66.3M (+82% YoY), adjusted EPS of $0.74, free cash flow of $64.1M, and accelerated deleveraging to ~2.3x pro forma with a target of ≤2.0x by year-end.
• Management highlighted its AI-enabled, payer-agnostic operating system, saying embedded AI agents are already improving outcomes and operations (24% higher gap-closure, 30% higher annual wellness completion, and much faster claims payment) and that benefits should compound over time.
• The business now serves ~1.55M members in value-based arrangements, with ~80% of Care Partners revenue and ~40% of owned membership in full-risk contracts; new full-risk cohorts are tracking to underwriting but Medicaid and Exchange enrollment trends were mixed.
• Prospect integration is on track — gross provider retention >99%, synergies tracking toward the high end of the $12–15M annual target, and Prospect is performing ahead toward ~$80M annualized adjusted EBITDA.
• The company reaffirmed 2026 guidance (revenue $3.8–4.1B, adjusted EBITDA $250–280M, FCF $105–132.5M), gave Q2 targets, and cited the 2027 Medicare Advantage rate notice and its encounter-based approach as structural regulatory tailwinds.

Astrana Health Price Performance

Shares of NASDAQ:ASTH traded up $0.83 during midday trading on Thursday, hitting $36.08. The company’s stock had a trading volume of 613,884 shares, compared to its average volume of 458,777. The business’s 50 day simple moving average is $27.38 and its 200 day simple moving average is $25.67. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.40 and a current ratio of 1.40. The company has a market cap of $2.01 billion, a P/E ratio of 78.44 and a beta of 0.98. Astrana Health has a 12-month low of $18.08 and a 12-month high of $36.20.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. BTIG Research decreased their price objective on shares of Astrana Health from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Truist Financial increased their price objective on shares of Astrana Health from $37.00 to $38.00 and gave the company a “buy” rating in a report on Friday, March 13th. Robert W. Baird increased their price objective on shares of Astrana Health from $37.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Zacks Research raised shares of Astrana Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, March 11th. Finally, Weiss Ratings raised shares of Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Astrana Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.86.

Hedge Funds Weigh In On Astrana Health

Several hedge funds and other institutional investors have recently modified their holdings of the business. Swiss National Bank lifted its stake in shares of Astrana Health by 1.2% in the third quarter. Swiss National Bank now owns 86,944 shares of the company’s stock worth $2,465,000 after buying an additional 1,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Astrana Health by 5.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock worth $799,000 after purchasing an additional 1,263 shares during the last quarter. Deutsche Bank AG increased its position in Astrana Health by 3.9% during the fourth quarter. Deutsche Bank AG now owns 41,265 shares of the company’s stock worth $1,024,000 after purchasing an additional 1,550 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Astrana Health by 3.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 42,258 shares of the company’s stock worth $1,049,000 after purchasing an additional 1,562 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in Astrana Health by 5.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 43,855 shares of the company’s stock worth $1,270,000 after purchasing an additional 2,285 shares during the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.